Priveterra Acquisition Corp. - Class A
News
Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
Business Wire Priveterra Acquisition Corp. II (NASDAQ: PMGMU, PMGM, PMGMW) (the Company) today announced that on April 29, 2024, the Company received a notice (the 10-K Notice) from the staff of the Nasdaq Listing...\n more…
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
Globe Newswire Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the preventive treatment of episodic migraine is anticipated to readout this fall $50 million financing provides...\n more…
Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.
Business Wire Priveterra Acquisition Corp. (Nasdaq: PMGM) (Priveterra), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the Business...\n more…
Priveterra Acquisition gets NYSE nod for listing upon merging with AEON Biopharma
SeekingAlpha.com: All News Priveterra Acquisition (PMGM) said Monday that the new AEON common stock and warrants have been approved to be listed on NYSE American LLC once it has merged with AEON Biopharma.Trading...\n more…
Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.
Business Wire Priveterra Acquisition Corp. (Nasdaq: PMGM) (Priveterra and, after the consummation of its pending business combination (the Business Combination) and following its name change to AEON Biopharma, Inc., New AEON) today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common...\n more…